Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)

PHASE3CompletedINTERVENTIONAL
Enrollment

454

Participants

Timeline

Start Date

May 27, 2019

Primary Completion Date

March 17, 2021

Study Completion Date

April 1, 2021

Conditions
Hypercholesterolemia
Interventions
COMBINATION_PRODUCT

EZ 10 mg/Ator 10 mg

FDC of EZ10 mg/Ator 10mg

COMBINATION_PRODUCT

EZ 10 mg/Ator 20 mg

FDC of EZ10 mg/Ator 20mg

DRUG

Atorvastatin

Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets

DRUG

Placebo for FDC EZ/Ator

A single placebo tablet administered orally QD for 84 days

DRUG

Placebo for atorvastatin

Two placebo tablets matching atorvastatin administered orally QD for 84 days

Trial Locations (30)

100024

Beijing Anzhen Hospital. Capital Medical University ( Site 0001), Beijing

100049

Aero Space center hospital ( Site 0003), Beijing

100050

Beijing Friendship Hospital ( Site 0005), Beijing

110016

The People's Hospital of Liaoning Province-Cardiovascular ( Site 0022), Shenyang

130021

Ji Lin Province People Hospital ( Site 0016), Changchun

130033

China-Japan Union Hospital of Jilin University ( Site 0015), Changchun

136000

Central People s Hospital of Siping ( Site 0046), Siping

150001

The first affiliated Hospital of Harbin Medical University ( Site 0009), Haerbin

163001

Daqing Oilfield General Hospital ( Site 0010), Daqing

200032

Zhongshan Hospital Fudan University ( Site 0049), Shanghai

200065

Shanghai Tongji Hospital ( Site 0031), Shanghai

210009

Zhongda Hospital Southeast University ( Site 0045), Nanjing

210011

The Second Affiliated Hospital of Nanjing Medical University ( Site 0020), Nanjing

215006

First Affiliated Hospital of Soochow University ( Site 0048), Suzhou

221000

The Affiliated Hospital of Xuzhou Medical University ( Site 0017), Xuzhou

225001

Subei People's Hospital ( Site 0040), Yangzhou

300121

Tianjin Union Medicine Centre ( Site 0032), Tianjin

315010

Ningbo First Hospital ( Site 0042), Ningbo

317000

Taizhou Hospital of Zhejiang Province ( Site 0035), Taizhou

323000

People s Hospital of Lishui City ( Site 0036), Lishui

325000

The First Affiliated Hospital of Wenzhou Medical University ( Site 0034), Wenzhou

330006

Second Affiliated Hospital of Nanchang University ( Site 0038), Nanchang

400013

Chongqing General Hospital ( Site 0037), Chongqing

410000

The Third Xiangya Hospital of Central South University ( Site 0013), Changsha

410005

Hunan Provincial People's Hospital ( Site 0011), Changsha

510080

Guangdong General Hospital ( Site 0006), Guangzhou

The First Affiliated Hospital.Sun Yat-sen University ( Site 0007), Guangzhou

510210

Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 0008), Guangzhou

730030

Lanzhou University Second Hospital ( Site 0041), Lanzhou

014010

The First Affiliated Hospital of Baotou Medical College ( Site 0025), Baotou

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT03768427 - Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) | Biotech Hunter | Biotech Hunter